Miller Rickey C, Steinbach Alison
Department of Pharmacy, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA Duquesne University, Pittsburgh, PA, USA University of Pittsburgh, Pittsburgh, PA, USA
Department of Pharmacy, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA.
J Pharm Pract. 2014 Oct;27(5):453-60. doi: 10.1177/0897190014546113.
Myelosuppression is a dose-limiting adverse effect with antineoplastic therapy and nonchemotherapy medications. Clinicians have data and guidelines to provide direction for the management of neutropenia and thrombocytopenia in patients with malignancies. Clinical situations outside oncology extrapolate these data along with limited data sets for those patients who demonstrate myelosuppressive effects from medications that are not traditionally considered cytotoxic. Pharmacological treatments can be used to help ameliorate the myelosuppressive toxicities. Recombinant technology has provided growth factors to counteract or lessen the degree of toxicity from myelosuppressive medications including chemotherapy. Clinical strategies and future trends on how to mitigate medication-related myelosuppression are discussed.
骨髓抑制是抗肿瘤治疗和非化疗药物的剂量限制性不良反应。临床医生有数据和指南可为恶性肿瘤患者中性粒细胞减少和血小板减少的管理提供指导。肿瘤学以外的临床情况会将这些数据与有限的数据集一起外推，这些数据集针对那些因传统上不被视为细胞毒性的药物而表现出骨髓抑制作用的患者。药物治疗可用于帮助改善骨髓抑制毒性。重组技术提供了生长因子，以抵消或减轻包括化疗在内的骨髓抑制药物的毒性程度。本文讨论了减轻药物相关骨髓抑制的临床策略和未来趋势。
